NVR 3778

Drug Profile

NVR 3778

Alternative Names: NVR-1221; NVR-3-778

Latest Information Update: 24 Mar 2016

Price : $50

At a glance

  • Originator Novira Therapeutics
  • Class Antivirals; Small molecules
  • Mechanism of Action Capsid protein inhibitors; Viral core protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 04 Mar 2016 Novira Therapeutics completes enrolment in a phase Ia/Ib trial for Hepatitis B in New Zealand (NCT02112799)
  • 04 Dec 2015 Novira Therapeutics was acquired by Johnson & Johnson
  • 04 Nov 2015 Novira plans a phase II trial for Chronic Hepatitis B virus (HBV) infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top